Key Biosimilars Events of March 2026

Why It Matters

The wave of approvals and partnerships accelerates biosimilar competition, promising lower biologic drug costs and broader patient access worldwide.

Key Takeaways

• Celltrion adds IV liquid Remsima across EU markets
• Avtozma SC offers first US SC biosimilar to Actemra
• Samsung Bioepis partners Sandoz for up to five biosimilars
• Formycon secures EU launch rights for Eylea biosimilar
• Teva’s Ponlimsi gains FDA approval, expanding osteoporosis market

Pulse Analysis

Regulatory bodies across Europe, the United States, Japan, and China continued to fast‑track biosimilar pathways in March, delivering a string of approvals that underscore the maturity of the market. Celltrion’s liquid Remsima IV addresses storage challenges in European hospitals, while its Avtozma SC provides a convenient sub‑cutaneous option for rheumatology patients in the U.S. These launches, alongside Teva’s Ponlimsi approval for osteoporosis, reflect a broader trend of biosimilars matching reference products in efficacy and safety, thereby reinforcing payer confidence and encouraging formulary inclusion.

Strategic alliances are reshaping global distribution networks, as Samsung Bioepis and Sandoz combine development expertise with commercial reach to bring up to five new biosimilars to market. Formycon’s settlement with Regeneron and Bayer unlocks Eylea’s high‑value ophthalmology segment across Europe and emerging markets, while Bio‑Thera’s expanded pact with India’s Intas leverages local manufacturing to improve affordability in a price‑sensitive region. Such collaborations reduce time‑to‑market, share regulatory risk, and create diversified revenue streams for both innovators and generic players.

Pipeline robustness and manufacturing scalability are equally critical. Prestige Biopharma’s Phase‑III SAMSON‑II data confirm clinical parity of HD204 with Avastin, positioning it for imminent regulatory submissions. Meanwhile, Cytiva’s FlexFactory partnership with Yoshindo aims to establish a modular biosimilar production line in Japan by 2028, ensuring supply resilience. Henlius’s IND clearance for an Opdivo biosimilar and multiple concurrent programs (HLX17, HLX13, HLX15‑SC) illustrate China’s growing R&D capabilities. Collectively, these developments suggest a tightening of biosimilar margins, heightened competition, and ultimately, more cost‑effective biologic therapies for patients worldwide.